You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)附屬夥晶泰科技開發治療惡性腫瘤小分子新藥
阿思達克 03-18 08:46
中國生物製藥(01177.HK)公佈,其附屬正大天晴與晶泰科技達成戰略合作,雙方將針對高難度靶點共同開發小分子新藥,用於惡性腫瘤治療。晶泰科技將利用其人工智能和高精度計算化學等技術平臺,完成化合物的生成、評估、優化等工作,聚焦小分子抗腫瘤創新藥物的發現和優化。 集團期望通過與晶泰科技的戰略合作,實現雙方強強聯合、優勢互補,加速針對高難度抗腫瘤靶點的新藥發現,開發出高質量的腫瘤治療藥物,滿足腫瘤患者的迫切治療需求。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account